With less than two weeks to go in 2016, there are some clear-cut winners in healthcare and some pretty dismal performances as well. The two benchmarks we watch carefully are the S&P 500 and the S&P 500 Healthcare sector as…continue reading →
Around this time each year, the pundits offer their “lists” of predictions or trends to watch for in the upcoming year. We all like to look at lists, mostly because they are short, sometimes fun, and on rare occasion may…continue reading →
For investors in Merck and Bristol Myers, it's a nail-biting weekend as Copenhagen hosts the 2016 European Society of Medical Oncology (ESMO) Congress. Here's what's a stake: Last December in our inaugural edition, In Sickness and Wealth featured two big…continue reading →
Can Socially-responsible Investing pay Dividends – to Investors and Humanity? Over the past 30 years, socially responsible investing has grown like Spring dandelions in my backyard. Back in the 1990s there were a handful of mutual funds that invested in “doing well…continue reading →
Where do popular television and science intersect? It’s not so far-fetched to ask where genetic innovation is taking us, and who will reign when the battle for power is decided. Companies that are great innovators have an edge on their competition.…continue reading →
Sometimes we fail to deliver better healthcare, not because a treatment doesn’t exist or science can’t develop one, but because it can’t survive the logistics of access, delivery, and sustainability. Good business is investing in activities that can achieve both... In Sickness and Wealth... as we explore innovative companies and how they deliver value.
David Lerman / Jodie Warner - Editors